HealthCare Ventures

HealthCare Ventures is a life science venture capital firm that invests in early clinical stage companies which transform patient care.

Business Model:

Revenue: $6.5M

Employees: 2-10

Rankings

Detailed HealthCare Ventures Information

Geographic Data

HealthCare Ventures headquarters map

Address: 47 Thorndike St

City: Cambridge

State: MA

Zip: 02141

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

9,513,354Website Global Rank

147Website Monthly Traffic

Twitter Followers

Description

HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.

Contact Phone:
+16172524343

Contact Email:

Announced Date Company Transaction Money Raised
6/2011 Apellis Pharmaceuticals Series A 0
9/2014 Colorescience Series B 15M
1/2011 TetraLogic Pharmaceuticals Series C 0
2/2003 Xanthus Pharmaceuticals Series A 0
9/2010 DecImmune Therapeutics Venture Round 3.2M
12/2005 GlobeImmune Series B 34.3M
10/2006 Tolerx Series D 61M
10/2009 Xanodyne Venture Round 0
6/2009 VaxInnate Series D 30M
3/2010 Seahorse Bioscience Series D 5M
7/2008 MiddleBrook Pharmaceuticals, Inc Post-IPO Equity 100M
6/2012 GITR Venture Round 1M
3/2005 Tolerx Series D 31M
11/2007 Ascent Therapeutics Series A 19M
2/2011 CellNovo Series B 48.3M
6/2003 Orqis Medical Series C 25M
10/2013 Pathogenetix Series C 10M
8/2007 BioProcessors Series C 10M
6/2006 TetraLogic Pharmaceuticals Series B 36M
8/2011 Pathogenetix Series B 4M
9/2002 CellGate Series D 10M
1/2008 CellNovo Series A -
6/2014 Senseonics Venture Round 0
8/2011 Cleveland HeartLab Series B 0
2/2008 Advancis Pharmaceutical Post-IPO Equity 21M
4/2007 Radius Health Series B 57.5M
11/2002 Dynogen Pharmaceuticals Series A 13.3M
2/2006 Catalyst Biosciences Series B 30M
7/2003 BioProcessors Series B 13M
3/2004 TetraLogic Pharmaceuticals Series A 8M
10/2008 InfaCare Pharmaceutical Series B 28M
6/2001 Orqis Medical Series B 5.2M
4/2004 Cardiokine Series A 37M
3/2008 Trevena Series A 24M
5/2006 Avidia Series C 43.8M
10/2003 Critical Therapeutics,Inc. Series B 56M
3/2004 VaxInnate Series B 23.1M
10/2006 VaxInnate Series C 40M
1/2007 Sequoia Pharmaceuticals Series C 35M
9/2011 Theraclone Sciences Series B 10.6M
4/2013 Catalyst Biosciences Post-IPO Equity 5.1M
8/2010 TetraLogic Pharmaceuticals Series C 0
1/2003 Tolerx Series C 35M
5/2001 CellGate Series C 19.2M
7/2009 PharmAthene Post-IPO Secondary 19.3M
8/2010 Anchor Therapeutics Series B 10M
12/2008 Catalyst Biosciences Post-IPO Equity 40M
3/2007 Theraclone Sciences Series B 29M
10/2012 Promedior Series D 0
12/2011 Radius Health Private Equity Round 21.4M
11/2008 Radius Health Series C 15M
3/2013 Theraclone Sciences Series B 0
3/2010 Theraclone Sciences Venture Round 1.5M
7/2011 Radius Health Series C 66M
7/2004 SkinMedica Series D 30M
3/2012 Promedior Series D 21.5M
5/2006 Promedior Series A 0
4/2005 SkinMedica Series E 0
4/2006 SkinMedica Series E 0
6/2006 BioProcessors Series C 18M
1/2002 ActivBiotics Series A 17M
8/2008 Proteostasis Therapeutics Series A 45M
5/2006 Foldrx Pharmaceuticals Series B 43M
8/2011 Vaxxas Series A 16.2M
3/2007 Orqis Medical Series D 12M
5/2006 Cardiokine Series B 50M
10/2001 Tolerx Series B 17M
11/2011 Pathogenetix Series B 7.5M
7/2008 Pathogenetix Series A 4.4M
9/2011 Tensha Therapeutics Series A 15M
9/2020 Colorescience Debt 30M
7/2002 Metaphore Pharmaceuticals Series C 30M
9/2015 Proteostasis Therapeutics Series B 37M
10/2010 Anexon Seed 500k
1/2016 Leap Therapeutics Venture Round -
7/2008 Stemgent Series A 6.5M
8/2011 Aciex Therapeutics Venture Round 8M
7/2011 nanoMR Series B 13M
11/2007 BIKAM Pharmaceuticals Series A 11M
3/2009 Seahorse Bioscience Series D 6M
7/2010 Trevena Series B 35M
11/1999 More.com Series C 43M
10/2010 Dicerna Pharmaceuticals Series B 4M
10/2004 PharmAthene Series B 50M
7/2007 Xanodyne Series A 25M
2/2015 Vaxxas Series B 0
6/2003 GlobeImmune Series A 8M
6/2011 Stemgent Series B 10.6M
3/2005 Sequoia Pharmaceuticals Series B 22M
7/2008 MiddleBrook Pharmaceuticals, Inc Post-IPO Equity 100M
1/2003 PharmAthene Series A 15M
6/2010 Foldrx Pharmaceuticals Venture Round 29M
2/2013 DecImmune Therapeutics Venture Round 2.3M
4/2002 Replidyne Series A 13M
6/2003 CellGate Series E 43.7M
11/2009 Stemgent Debt Financing 2.7M
7/2008 Sierra Neuropharmaceuticals Inc. Series A 0
10/2012 Cleveland HeartLab Series B 14.7M
7/2011 Cool Energy Venture Round 1M
12/2006 Xanthus Pharmaceuticals Series B 0
11/2011 Mosaic Biosciences Series A 1M
11/2002 Critical Therapeutics,Inc. Series A 10M
7/2005 Xanodyne Series A 170M
6/2004 Xanodyne Venture Round 20M
6/2015 Galleon Pharmaceuticals Series B 10M
6/2001 NitroMed Series E 0
12/2006 RedPath Integrated Pathology Series A 0
12/2003 Xanthus Pharmaceuticals Series B 0
9/2020 Colorescience Debt Financing 0
1/2016 Leap Therapeutics Venture Round -
9/2015 Proteostasis Therapeutics Series B 0
6/2015 Galleon Pharmaceuticals Series B 0
2/2015 Vaxxas Series B 0
9/2014 Colorescience Series B 0
6/2014 Senseonics Venture Round 0
10/2013 Pathogenetix Series C 0
4/2013 Catalyst Biosciences Post-IPO Equity 0
3/2013 Theraclone Sciences Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research
CoBee's Logo
Copyright © CoBee 2022. All Rights Reserved.